Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine is under clinical development by Nanolek and currently in Phase III for Human Papillomavirus Infections. According to GlobalData, Phase III drugs for Human Papillomavirus Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine overview

Vaccine candidate is under development for the prevention of human papillomavirus infections. The vaccine candidate is a recombinant vaccine comprising of four serotypes (6, 11, 16, 18). It is administered through intramuscular route.

Nanolek overview

Nanolek is a biopharmaceutical company that develops vaccines and drugs to prevent and treat cancer and infectious diseases. The company’s product portfolio includes vaccines for diphtheria, tetanus, Haemophilus influenzae type b infection and polio, biotechnology products targeting rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, ankylosing spondylitis, and Hunter syndrome. Nanolek also offers chemical products to treat HIV, cytomegalovirus, myocardial infarction, diabetic nephropathy, diffuse renal diseases, chronic heart failure and other diseases. The company’s Efferon LPS device is used for extracorporeal blood purification. Nanolek is headquartered in Moscow, Russia.

For a complete picture of Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.